Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia
overview of systematic reviews
Keywords:
Schizophrenia, Antipsychotic agents, Dopamine antagonists, Aripiprazole [substance name], Quetiapine [substance name], RisperidoneAbstract
CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs) on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline) (1966-2009), Controlled Trials of the Cochrane Collaboration (2009, Issue 2), Embase (Excerpta Medica) (1980-2009), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) (1982-2009). There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.
Downloads
References
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15- year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85.
Barnes TRE, Buckley P, Schulz SC. Treatment-resistant schizophrenia. In: Hirsch SR, Weinber- ger D, editors. Schizophrenia. 2nd ed. Oxford: Blackwell Publishing; 2003. p. 489-516.
Altamura AC, Bassetti R, Cattaneo E, Vismara S. Some biological correlates of drug resis- tance in schizophrenia: a multidimensional approach. World J Biol Psychiatry. 2005;6 suppl 2:23-30.
Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997;154(4):475-82.
Henna J, Oliveira JR, Mello MF, et al. Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients. Schizophrenia Research. 1999;36(1-3):281-2.
National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antip- sychotic drugs for the treatment of schizophrenia. London: National Institute for Clini- cal Excellence; 2002. Available from: http://www.crd.york.ac.uk/crdweb/ShowRecord. asp?View=Full&ID=32002000858. Accessed in 2010 (Apr 29).
Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophre- nia. Schizophr Bull. 1990,16(4):551-61.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96.
El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD004578.
Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophre- nia. Cochrane Database Syst Rev. 2008;(3):CD006617.
Nussbaum AM, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;(2):CD006369.
Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Data- base Syst Rev. 2004;(2):CD000967.
Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000440.
Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antip- sychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;(3):CD002306.
Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD005237.
Moher D, Tsertsvadze A, Tricco AC, et al. When and how to update systematic reviews. Co- chrane Database Syst Rev. 2008(1) MR000023.
Carson WH, Ingenito GG, McQuade RD, Stock EG, Iwamoto T. [Schizophrenia; safety/tolera- bility of aripiprazole]. In: XIIth World Congress of Psychiatry; Aug 24-29; Yokohama, Japan; 2002. [abstract].
Kane J, William HCJ, Kujawa MJ, et al. Aripiprazole vs. perphenazine in treatment-resistant schizophrenia. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA; 2003. [NR537].
Daniel DG, Stock EG, Wilber CH, et al. Intramuscular aripiprazole in acutely agitated psycho- tic patients. In: 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA; 2004. [APA Conference abstracts NR612].
Oren D, Marcus R, Kostic D, et al. Efficacy and Safety of Intramuscular Aripiprazole, Halope- ridol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder. In: XX International Congress on Schizophrenia Research; 2005 April 2-6, Georgia, USA; 2005. Schizophrenia Bulletin 2005;31:399. [abstract].
Carson WH, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan; Puerto Rico; 2000. [abstract].
Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology. 2000;10(Suppl 3):S309-10.
Csernansky JG. Treatment of schizophrenia: preventing the progression of disease. Psychiatr Clin North Am. 2003;26(2):367-79.
Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsycho- tic: overview of a phase II study result. International Journal of Neuropsychopharmacology. 2000;3(Suppl 1):S157.
Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1): S186.
Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-31.
Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213-23.
Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperido- ne extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo- controlled study. Schizophr Res. 2007;93(1-3):117-30.
Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for preven- tion of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-relea- se tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-70.
Tzimos A, Kramer M, Ford L, et al. A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. In: 25th Collegium Internationale Neuro-psychopharma- cologicum; 2006, Jul 9-13; Chicago, Illinois; 2006. [abstract]
Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone ex- tended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat. 2008;4(5):949-58.
Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizo- phrenia. Am J Psychiatry. 2009;166(6):691-701.
Hirsch S, Arvanitis L, Miller B, Smith A. A multicentre, double-blind, placebo-controlled com- parison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. European Neurop- sychopharmacology. 1994;4(3):384-5.
Link CGG, Arvanitis L. ‘Seroquel’ treatment of hospitalised patients with acute exacerba- tion of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double- blind comparison of low and high dosage regimens. European Neuropsychopharmacology 1995;5:346-7.
Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophre- nia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54(6):549-57.
Addington DE, Arvanitis LA. ‘Seroquel’ (quetiapine): an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study. In: 4th International Conference on Schi- zophrenia 1996: Breaking Down the Barriers; 1996, Oct 6-9; Vancouver, Canada; 1996. [abstract].
Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. European Neuropsychopharmacology. 1996;6(Suppl 3):148.
Arvanitis LA, Miller BG. Quetiapine, an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study. In: 149th Annual Meeting of American Psychiatric Associa- tion; 1996, May 2-9, New York, New York; 1996. [abstract].
Arvanitis LA, Miller BG, Kowalcyk BB. Efficacy of ‘Seroquel’ (Quetiapine Fumarate) in affecti- ve symptoms of schizophrenia. In: 36th Annual Meeting of the American College of Neurop- sychopharmacology; 1997, Dec 8-12, Waikoloa, Hawaii; 1997. [abstract].
Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-46.
Arvanitis LA, Miller BG, Study Group. ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial. Psychopharmacology Bulletin. 1966;32:391.
Borison RL, Arvanitis LA, Miller BG. A comparison of five fixed doses of ‘seroquel’ (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Re- search. 1996;18(2-3):132.
Borison RL, Arvanitis LA, Miller BG. A multiple fixed-dose, placebo-controlled trial with ‘sero- quel’ - An atypical antipsychotic. Biological Psychiatry. 1996;39(7):597-8.
Cantillon M. Quetiapine fumarate reduces aggression. In: 11th Annual Meeting of the Ame- rican Association for Geriatric Psychiatry; 1998, Mar 8-11, San Diego, California; 1998. [abstract].
Cantillon M, Goldstein JM. Efficacy of quetiapine fumarate in affective symptoms of schi- zophrenia. In: 151st Annual Meeting of the American Psychiatric Association; 1998, May 30 – Jun 4, Toronto, Ontario; 1998. [abstract].
Cantillon M, Goldstein JM. Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia. In: 151st Annual Meeting of the American Psychiatric Association; 1998, May 30 – Jun 4, Toronto, Ontario; 1998. [abstract].
Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): not different from placebo for EPS or prolactin. Biological Psychiatry. 1996;39:598.
Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. European Neuropsychopharmacology. 1996;6(Suppl 3):171.
Hong WW, Arvanitis LA, Miller BG. Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome or effect on plasma prolactin. In: 149th Annual Meeting of the American Psychiatric Association; 1996, May 2-9, New York, New York; 1996. [abstract].
Hong WW, Miller BG, Arvanitis LA. The atypical profile of ‘Seroquel’ (ICI 204,636) is suppor- ted by the lack of sustained elevation of plasma prolactin in schizophrenic patients. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11-15, San Juan, Puerto Rico; 1995. [abstract].
Fabre LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indica- tion of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17(3):366-78.
Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psycho- pharmacol. 1996;16(2):158-69.
Arvanitis L, Miller B, Fennimore J. A multicentre, placebo-controlled double-blind evaluation of SeroquelTM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. European Neuropsychopharmacology. 1994;4(3):385.
Link CGG, Arvanitis L. SeroquelTM treatment of hospitalised patients with acute exacerba- tion of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double- blind comparison of low and high dosage regimens. European Neuropsychopharmacology. 1995;5(3):346-7.
Barzega G, Bogetto F, Maina G, Ravizza L. [Efficacia e tollerabilita dell’ antipsychotico atipico quetiapina: uno studio in doppio cieco]. Minerva Psichiatrica 1999;40:297-305.
Barzega G, Bogetto F, Maina G, Ravizza L. Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison. European Journal of Psychiatry 2000;14:221-32.
Fleischhacker WW, Link CCG, Horne B. A multicentre, double-blind, randomised comparison of dose and dose regimen of ‘Seroquel’ in the treatment of patients with schizophrenia. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11- 15, San Juan, Puerto Rico; 1995. [abstract].
King DJ, Link CGC. ‘Seroquel’ (ICI 204636): an atypical antipsychotic - results from Phase
III. European Neuropsychopharmacology 1996;6:202.
King DJ, Link CGG. Seroquel (ICI 204636): an atypical antipsychotic results from Phase
III. In: XXth Collegium Internationale Neuro-psychopharmacologicum; 1996, June 23-27, Melbourne, Australia; 1996. [abstract].
King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Se- roquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998;137(2):139- 46.
Reuther E, Degner D. Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 (‘Seroquel’). Nervenarzt 1996;67:S192.
Purdon SE, Malla A, Labelle A, Litt W. Long-term treatment of quetiapine improves cognitive function in schizophrenia. Biological Psychiatry. 2000;47(8 Suppl 1):S42.
Purdon SE, Malla A, Labelle A, Litt W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26(2):137-49.
Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95-105.
Fleishhacker W, Link C, Hurst B. ICI 204,636 (Seroquel) - a putative new antipsychotic: results from Phase III trials. Schizophrenia Research 1996;18:32.
Hellewell JSE, Hurst BC, Link CGG. Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic (‘Seroquel’-ICI 204,636). European Neuropsychopharmacolo- gy 1996;6:123.
Link C, Farrow L. ‘Seroquel’™ (ICI 204, 636) EPS and prolactin - comparison with halo- peridol. In: 10th World Congress of Psychiatry; 1996, Aug 23-28, Madrid, Spain; 1996. [abstract].
Empfield JR, Clayton J, Isaac M, et al. AstraZeneca AB. Metabotropic glutamate receptor-po- tentiating isoindolones. [Patent application]. Available from: http://www.faqs.org/patents/ app/20090149505. Accessed in 2010 (May 27).
Link C, Smith A, Miller B, Ryan J, Study Group. A multicentre, double-blind, controlled compa- rison of SeroquelTM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. European Neuropsychopharmacolo- gy. 1994;4(3):385.
Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96(4):265-73.
Buckley PF, Goldstein JM, Emsley RA. Comparison of quetiapine and haloperidol in treat- ment-resistant schizophrenia. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
Emsley RA, Bailey P, Jones AM, Raniwalla JTI. Efficacy of quetiapine fumarate in partial responders. In: Annual Meeting of the American Psychiatry Association; 1999, Washington, USA; 1999. [abstract].
Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizo- phrenia: efficacy of quetiapine versus haloperidol. European Neuropsychopharmacology 2001;11:S264.
Emsley RA, Raniwalla J, Bailey P, Jones AM. [Efficacy and tolerability of ‘Seroquel’ compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment]. European Neuropsychopharmacology. 1999;9(Suppl 5):S267.
Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstra- ted, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000;15(3):121-31.
Emsley RA, Raniwalla J, Jones AM, PRIZE Study Group. Efficacy of seroquel in trea- ting all of the positive and negative symptoms of schizophrenia. Schizofrenia Research. 2000;41(1):203.
Goldstein JM, Buckley P. Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan, Puerto Rico; 2000. [abstract].
Nasrallah HA, Rennie P, Altman C. Patterns of response in patients with schizophrenia par- tially responsive to fluphenazine and switched to quetiapine or haloperidol. European Neu- ropsychopharmacology. 2001;11(Suppl 3):S262.
Weiden PJ, Ashworth P. Switching from fluphenazine to quetiapine ameliorates extrapyrami- dal symptoms and neuroendocrine side effects in patients with schizophrenia. European Neuropsychopharmacology. 2001;11(Suppl 3):S262-S263.
Kudo Y, Nomura J, Ikawa G, et al. Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control. Rinsyo Iyaku. 2000;16:1807-42.
Kudo Y, Nomura J, Ikawa G, et al. Clinical trial of quetiapine in schizophrenia - efficacy and tolerability of quetiapine: a comparative double-blind study with masopramine in schizo- phrenic patients. In: Annual Meeting of the World Psychiatric Association; 1999, Aug 6-11; Hamburg, Germany; 1999. [abstract].
Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolera- bility of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839-54.
Tandon R. Quetiapine and risperidone in outpatients with schizophrenia: subanalysis of the QUEST trial. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005;28(4):163-8.
Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetia- pine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24(1):1-13.
Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, ha- loperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16(1):38-44.
Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25-40.
Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chro- nic schizophrenic inpatients: a multicentre double-blind comparitive study. Acta Psychiatr Scand. 1992;85(4):295-305.
Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treat- ment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88(6):395-402.
Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the tre- atment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995;91(4):271-7.
Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-35.
Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993;34(2):179-90.
Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi- national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166(6):712-26; discussion 727-33.
Potkin SG, Gutierrez R. In: 150th Annual Meeting of the American Psychiatric Association; 1997, May 17-22; San Diego, California; 1997. [abstract].
Bouchard RH, Demers MF, Merette C, Pourcher E. Classical neuroleptics (CNLP) vs risperdo- ne (RIS) interim 12 months efficacy of a long-term, naturalistic study in schizophrenics. In: 11th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
Mahmoud RA, Engelhart LM, Risperidone Outcome Study of Effectiveness (ROSE) Group Janssen Research Foundation. Risperidone versus conventional antipsychotics in usual care: a prospective randomised effectiveness trial of outcomes for patients with schizo- phrenia and schizoaffective disorder. In: 11th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
Namjoshi M, Young C, Huang L, Edgell ET, Breier A. Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizo- phrenia: results from a US random study. International Journal of Neuropsychopharmacolo- gy In: 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002, Jun 23-27; Montreal, Canada; 2002. [abstract].
Namjoshi M, Young Cm, Huang L, Edgell ET, Breier A. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol. 2002;(Suppl 3): S315.
Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olan- zapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765-74.
Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11(6):638-47.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus rispe- ridone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychophar- macol. 1997;17(5):407-18.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81(1):1-15.
Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophre- nia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Cana- dian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3): 249-58.
Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharma- cology. 2003;28(1):182-92.
Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev. 2003;(4):CD004161.
Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-32.
Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for pa- tients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperi- done for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2008;23(6):455-63.
Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90-4.
Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-23.
Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472-82.
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-63.
Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr. 2005;27(3): 178-84.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first- episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008;371(9618):1085-97.
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-57.
